Table 1

Clinical trials of TAA-directed cancer vaccines

TAAsDiseaseVaccine interventionTrial numberPhaseStatusLocations
HER2Breast cancerAdHER2/neu dendritic cell vaccineNCT01730118Phase 1CompletedNational Institutes of Health Clinical Center
MUC1Lung carcinomaMUC1 Peptide-Poly-ICLC VaccineNCT03300817Phase 1RecruitingMayo Clinic in Rochester/University of Pittsburgh Cancer Institute
SurvivinRecurrent epithelial ovarian cancerDC-006 vaccineNCT01334047Phase 1/2TerminatedOslo University Hospital-Norwegian Radium Hospital
hTERTMetastatic prostate cancerhTERT mRNA DCNCT01153113Phase 1/2WithdrawnUniversity of Florida
NY-ESO-1Prostate cancer/bladder cancer/non-small cell lung cancerNY-ESO-1 plasmid DNA Cancer VaccineNCT00199849Phase 1CompletedNew York Presbyterian Hospital/UT MD Anderson Cancer Center Houston
MAGE-A3Squamous cell carcinoma of the head and neckHPV-16 vaccine/MAGE-A3NCT00257738Phase 1CompletedUniversity of Maryland School of Medicine Baltimore
TyrosinaseMelanomaMontanide ISA 51NCT00184067Phase 2TerminatedUSC/Norris Comprehensive Cancer Center
gp100Melanomagp100 human melanoma peptide vaccineNCT00001439Phase 1CompletedNational Cancer Institute
MART-1Malignant melanomaCYT004-MelQbG10NCT00306566Phase 1/2CompletedCentre Pluridisciplinaire d’Oncologie & LICR